Picornavirus proteins share antigenic determinants with heat shock proteins 60/65.
Immunological cross-reactions between enteroviruses and islet cell autoantigens have been suggested to play a role in the etiopathogenesis of insulin dependent diabetes mellitus (IDDM). In the nonobese diabetic mouse, an autoimmune model of IDDM, one of the reactive beta cell autoantigens is the heat shock protein 60 (HSP60). These studies were prompted by sequence homology discovered between the immunogenic region in HSP60 and two regions in enterovirus capsid proteins, one in the VP1 protein and the other in the VP0, the precursor of VP2 and VP4 proteins. Possible immunological cross-reactions between enterovirus proteins and heat shock proteins were studied by EIA and immunoblotting by using purified virus preparations, viral expression proteins VP1 and VP0, and recombinant HSP60/65 proteins, and corresponding polyclonal antisera. The HSP60/65 family of proteins is highly conserved and there is a striking degree of homology between bacterial and human heat shock proteins. Rabbit antibodies to HSP65 of Mycobacterium bovis that reacted with human HSP60 were also found to recognise capsid protein VP1 of coxsackievirus A9, VP1, and/or VP2 of coxsackievirus B4. Both viruses were also recognised by antisera raised against HSP60 of Chlamydia pneumoniae. In addition to the capsid proteins derived from native virions, antisera to both bacterial HSP proteins recognised expression protein VP1 of coxsackievirus A9. The cross-reactivity was also demonstrated the other way around; antisera to purified virus particles reacted with the HSP 60/65 proteins to some extent. These results suggest that apart from the well-documented sequence homology between the 2C protein of coxsackieviruses and the beta-cell autoantigen glutamic acid decarboxylase, there are other motifs in picornavirus proteins homologous to islet cell autoantigens, which might induce cross-reacting immune responses during picornavirus infections.
Härkönen
T
T
Enterovirus Laboratory, National Public Health Institute, Helsinki, Finland. taina.harkonen@ktl.fi
Puolakkainen
M
M
Sarvas
M
M
Airaksinen
U
U
Hovi
T
T
Roivainen
M
M
D000907:Antibodies, Bacterial / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000096:biosynthesis / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D001426:Bacterial Proteins; D015153:Blotting, Western; D018834:Chaperonin 60 / Q000276:immunology*; D018833:Chaperonins / Q000276:immunology*; D003429:Cross Reactions; D003920:Diabetes Mellitus / Q000276:immunology*; D000939:Epitopes / Q000032:analysis*; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D007124:Immunoenzyme Techniques; D010849:Picornaviridae / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000276:immunology*
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D000956:Antigens, Viral; D001324:Autoantigens; D001426:Bacterial Proteins; D018834:Chaperonin 60; D000939:Epitopes; D007106:Immune Sera; D011993:Recombinant Fusion Proteins; D014759:Viral Envelope Proteins; C074119:heat-shock protein 65, Mycobacterium; D018833:Chaperonins